Well that seals it then.
With Maria in a strategic role at Roquefort and able to keep an eye on any deals being made I would expect that if Anagenics was in a position to ever need their own MK patents for some development they could apply to Roquefort who would then utilize Lyramids license at arms length.
So all the ballyhoo about being sold for peanuts is mistaken.
They still have access to all their own patents through Roquefort, Roquefort is doing the hard lifting in the meantime with MK.
A sale by Roquefort of the whole Lyramid license and company to another party doesnt alter anything.
IMHO
- Forums
- ASX - By Stock
- AN1
- AN1 Quarterly Trends
AN1 Quarterly Trends, page-15
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LGP
Record revenue of $10.2 million as European demand drives 40% quarterly growth, with $1 million in operating cash inflow and $0.5 million in cost savings forecast
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable